Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs.

Fried R, Monnat M, Seidenberg A, Oppliger R, Schmid P, Herold M, Isler M, Broers B, Kölliker C, Schönbucher P, Frei M, Huber M.

Digestion. 2008;78(2-3):123-30. doi: 10.1159/000173733. Epub 2008 Nov 21.

PMID:
19023207
2.
3.

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.

Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB.

Gastroenterology. 2009 Mar;136(3):856-62. doi: 10.1053/j.gastro.2008.11.037. Epub 2008 Nov 19.

PMID:
19135998
4.

Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration.

Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC Jr, Monto A, Rossi SJ, Sulkowski MS.

Am J Gastroenterol. 2008 Nov;103(11):2757-65. doi: 10.1111/j.1572-0241.2008.02065.x. Epub 2008 Aug 5.

PMID:
18684176
5.

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.

Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB, Lamour F, Lardelli P; PEGASYS Study NR16071 Investigator Group.

Gastroenterology. 2004 Dec;127(6):1724-32.

PMID:
15578510
6.

[Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].

Kang MJ, Jung EU, Park SW, Choi P, Kim JH, Park SJ, Park ET, Lee YJ, Lee SH, Seol SY.

Korean J Hepatol. 2008 Sep;14(3):318-30. doi: 10.3350/kjhep.2008.14.3.318. Korean.

7.

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.

Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, McHutchison JG.

J Hepatol. 2008 Aug;49(2):163-9. doi: 10.1016/j.jhep.2008.03.027. Epub 2008 Apr 29.

PMID:
18486984
8.

Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open-label study.

Sulkowski M, Reindollar R, Thomas DL, Brinkley-Laughton S, Hudson M, Yu J.

BioDrugs. 2002;16(2):105-9.

PMID:
11985484
9.

Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.

Langlet P, D'Heygere F, Henrion J, Adler M, Delwaide J, Van Vlierberghe H, Mulkay JP, Lasser L, Brenard R, Horsmans Y, Michielsen P, Laureys A, Nevens F.

Aliment Pharmacol Ther. 2009 Aug 15;30(4):352-63. doi: 10.1111/j.1365-2036.2009.04052.x. Epub 2009 May 26.

10.

Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.

Belhadj N, Houissa F, Elloumi H, Ouakaa A, Gargouri D, Romani M, Kilani A, Kochlef A, Kharrat J, Ghorbel A.

Tunis Med. 2008 Apr;86(4):341-5.

PMID:
19476135
11.
12.

The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.

Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, Schena FP, Di Leo A, Francavilla A.

J Hepatol. 2007 May;46(5):768-74. Epub 2007 Feb 5.

PMID:
17383045
13.

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M.

Infection. 2008 Jun;36(3):250-5. doi: 10.1007/s15010-007-7132-6. Epub 2008 May 3.

PMID:
18458815
14.

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS.

Gastroenterology. 2009 Feb;136(2):496-504.e3. doi: 10.1053/j.gastro.2008.10.049. Epub 2008 Oct 29.

PMID:
19084016
15.

[Efficacy of combined antiviral therapy with pegylated interferon alpha-2a and ribavirin for chronic hepatitis C infection in intravenous drug users].

Ruzić M, Milotka F, Klasnja B, Pobor M, Svarc D, Jovelic A, Fabri I.

Srp Arh Celok Lek. 2010 Jan-Feb;138(1-2):43-9. Serbian.

16.
17.

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.

Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; Epic Study Group.

Gastroenterology. 2009 May;136(5):1618-28.e2. doi: 10.1053/j.gastro.2009.01.039. Epub 2009 Jan 22.

PMID:
19208349
18.

[Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C].

Kim KT, Han SY, Kim JH, Yoon HA, Baek YH, Kim MJ, Lee SW, Jang JS, Lee JH, Roh MH.

Korean J Hepatol. 2008 Mar;14(1):36-45. doi: 10.3350/kjhep.2008.14.1.36. Korean.

19.

Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.

Iacob S, Gheorghe L, Hrehoret D, Becheanu G, Herlea V, Popescu I.

J Gastrointestin Liver Dis. 2008 Jun;17(2):165-72.

20.

[Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study].

Kim JI, Kim SH, Lee BS, Lee HY, Lee TH, Kang YW, Lee HIe, Kim AN, Nam SW, Park BC, Chae HB, Kim SB, Song IH, Park JY, Kim HS.

Korean J Hepatol. 2008 Dec;14(4):493-502. doi: 10.3350/kjhep.2008.14.4.493. Korean.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk